Skip to content

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

ISSN 2167-8421, 2167-9223

2 papers in the library · 1 citation · publishing 2022-2024

Papers

Sort Most recent Most cited

ALSUntangled #77: Psilocybin

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration December 22, 2024 Bhavya Bakshi, Sandeep Yerraguntla, Carmel Armon et al. 1 citation

ALSUntangled reviews alternate and off-label treatments prompted by patient interest. Here, we review psilocybin, a chemical derived from mushrooms and belonging in the category of drugs known as psychedelics. Psilocybin has plausible mechanisms for slowing ALS progression because of its ability to cross the blood brain barrier and effect neurogenesis and inflammation. Currently, there are no...

DOI: 10.1080/21678421.2024.2441274 (opens in new tab) Psilocybin Neurogenesis Psychedelics hallucinogens Psychoactive drugs +8

An online non-meditative mindfulness intervention for people with ALS and their caregivers: a randomized controlled trial.

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration February 2022 Francesco Pagnini, Deborah Phillips, Anne Haulman et al.

Objectives: Mindfulness-based interventions seem to be effective in promoting QOL of ALS patients and caregivers, but most require substantial time. In the Langerian approach, mindfulness can be easily promoted with mental tasks and short lectures. This study aims to explore the impact of an ALS-specific online Langerian mindfulness training program on QOL of ALS patients. Methods: We developed...

DOI: 10.1080/21678421.2021.1928707 (opens in new tab) Full text (opens in new tab) Mindfulness Amyotrophic lateral sclerosis Caregivers Psychological intervention +1